Brokerages Downgrade Ranbaxy
  • Prabha Hedge
  • Jan 14 2014

January 14: Ranbaxy took a huge cut in trade after the U.S.FDA cited quality compliance issues at the company’s API unit in Punjab. And brokerages have given a thumbs down to Ranbaxy over this development. Bloomberg TV India’s Agam Vakil shares a detailed report.